|
|
Volumn 343, Issue 6176, 2014, Pages 1177-
|
|
Time for new schizophrenia Rx
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
NEUROLEPTIC AGENT;
AUTISM;
BIPOLAR DISORDER;
CAREGIVER;
COGNITIVE THERAPY;
DELUSION;
DRUG INDUSTRY;
EDITORIAL;
EMOTIONAL DISORDER;
HALLUCINATION;
HUMAN;
MOTIVATION;
NATIONAL HEALTH ORGANIZATION;
NEGATIVE SYNDROME;
NONHUMAN;
PRIORITY JOURNAL;
SCHIZOPHRENIA;
SPEECH DISORDER;
THOUGHT DISORDER;
ALZHEIMER DISEASE;
ARTHRITIS, RHEUMATOID;
DIABETES MELLITUS, TYPE 2;
DRUG DEVELOPMENT;
GENETICS;
INTERNATIONAL COOPERATION;
LUPUS ERYTHEMATOSUS, SYSTEMIC;
PRESCRIPTION;
TRENDS;
UNITED STATES;
ALZHEIMER DISEASE;
ANTIPSYCHOTIC AGENTS;
ARTHRITIS, RHEUMATOID;
DIABETES MELLITUS, TYPE 2;
DRUG DISCOVERY;
DRUG INDUSTRY;
DRUG PRESCRIPTIONS;
HUMANS;
INTERNATIONAL COOPERATION;
LUPUS ERYTHEMATOSUS, SYSTEMIC;
NATIONAL INSTITUTES OF HEALTH (U.S.);
SCHIZOPHRENIA;
UNITED STATES;
|
|
EID: 84896034967
PISSN: 00368075
EISSN: 10959203
Source Type: Journal
DOI: 10.1126/science.1252603 Document Type: Editorial |
|
Times cited : (14)
|
|
References (0)
|
